INTERCEPT IHI的封面图片
INTERCEPT IHI

INTERCEPT IHI

研究服务

Pioneering A Future Without Crohn's Disease

关注

关于我们

In a groundbreaking effort to change the future of Crohn’s Disease, 21 collaborative partners from Europe, North America and South Korea have joined forces in the INTERCEPT project to verify and clinically validate a panel of biomarkers and build a blood risk score that can identify individuals with a high risk of developing Crohn’s Disease. 10,000 healthy first-degree relatives of individuals with Crohn’s Disease will be recruited to further validate the biomarkers and risk score. From this group, 80 with the highest risk of developing Crohn’s Disease will take part in an innovative trial aimed at preventing full-blown disease development. INTERCEPT is setting its sights on a future where Crohn’s Disease is highly manageable or even avoidable; committing itself to improving the lives of patients and their families around the world. This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194780. The JU receives support from the European Union’s Horizon Europe Research and Innovation Programme and COCIR, EFPIA, Europa Bío, MedTech Europe, Vaccines Europe, and Ludger Ltd, Celltrion Inc. and Prometheus Laboratories Inc. Co-Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

网站
www.intercept-ihi.eu
所属行业
研究服务
规模
51-200 人

动态

关联主页

相似主页